Ology Bioservices Nets $16 Million in DoD Contracts

ALACHUA – Alachua based Ology Bioservices Inc., is receiving Department of Defense (DOD) biomanufacturing contacts valued at over $16 million. Through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA), DOD has awarded the company with three biomanufacturing contracts with a combined value of more than $16 million.

Ology Bioservices specializes in biologic drug substance manufacturing from early stage through commercial product. The company has 183,000 square feet of manufacturing, process development and QA/QC space in its state-of-the-art Advanced Development and Manufacturing Facility in Alachua. Ology Bioservices has more than 20 years of experience developing and manufacturing drugs and biologics for the U.S. government, with over $1.8 billion in government contracts awarded.

In the first program, valued at $8.5 million, Ology Bioservices will manufacture a conjugated vaccine candidate comprising the conserved protein from the bacterium Burkholderia pseudomallei and the adjuvant CPS-CRM-197. The vaccine candidate, developed at the University of Nevada, Reno, will be tested in a Phase 1 clinical trial and is being developed to prevent the disease melioidosis.

In the second program, valued at $4.6 million, Ology Bioservices will manufacture outer membrane vesicles from Burkholderia mallei as a potential vaccine against the bacterial disease glanders, an infectious disease primarily affecting horses. The vaccine candidate was developed at Tulane University. The material produced in this program will support a Phase 1 clinical trial.

In the third program, valued at $3.2 million, Ology Bioservices will manufacture a DNA vaccine against Venezuelan equine encephalitis to support a Phase 1 clinical trial. The vaccine was developed at the United States Army Medical Research Institute of Infectious Diseases.

“We are pleased to be working with DTRA on these important programs,” said Peter H. Khoury, President and CEO at Ology Bioservices. “The diverse biomanufacturing technologies employed in these three programs clearly demonstrate the capabilities of our team at Ology Bioservices and the functionality of the Advanced Development and Manufacturing Facility.”

The company’s infrastructure provides unique services to its clients, including full regulatory support from preclinical through licensure, clinical trial operational support and bioanalytical testing, as well as the FDA’s Current Good Manufacturing Practice (CGMP) regulations manufacturing up to Biosafety Level 3 (BSL3).

#     #     #

Email editor@

alachuatoday.com